Gland Pharma Limited — Investor Meet, 07-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Gland Pharma reported Q2 FY26 consolidated revenue of ₹1,486.9 Cr (+6% YoY) and EBITDA of ₹313.9 Cr (+6% YoY), with a 21% margin. PAT stood at ₹183.7 Cr (+12% YoY). H1 FY26 saw consolidated revenue of ₹2,992.5 Cr (+7% YoY) and EBITDA of ₹681.7 Cr (23% margin). The company anticipates a stronger second half, targeting mid-teen consolidated revenue growth for FY26. US revenue increased 8% YoY, supported by new launches and CDMO business. Cenexi's H1 EBITDA losses decreased to EUR 5 million, with a goal to be EBITDA positive from Q3 FY26, aiming for EUR 50 million revenue. Key growth drivers include the Dalbavancin launch, a ~₹150 Cr Colistimethate project, and expanding GLP-1 cartridge capacity to 140 million units by mid-next year. Management remains focused on complex injectables, biologics CDMO, and operational efficiencies.